Impetigo: Etiology and therapy

Current Clinical Topics in Infectious Diseases

Volumn , Issue 22, 2002, Pages 42-51

  Hirschmann, J V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADOLESCENT; BULLOUS SKIN DISEASE; CHILD; CLASSIFICATION; DERMATITIS; HUMAN; IMPETIGO; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PRESCHOOL CHILD; PREVALENCE; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DERMATITIS; HUMANS; IMPETIGO; PREVALENCE; SKIN DISEASES, VESICULOBULLOUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

EID: 0036982916     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (57)

1. Dajani AS, Fernen P, Wannamaker L. Endemic superficial pyoderma in children. Arch Dermatol 1973;108:517-522.
2. Dillon HC. Impetigo contagiosa: suppurative and non-suppurative complications. I. Clinical, bacteriologic, and epidemiologic characteristics of impetigo. Am J Dis Child 1968;115:530-541.
3. Wannamaker LW. Differences between streptococcal infections of the throat and of the skin. N Engl J Med 1970;282:23-30;78-85.
4. Tejani A, Ingulli E. Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts. Nephron 1990;55:1-5.
5. Schachner L, Taplin D, Scott GB, Morrison M. A therapeutic update of superficial skin infections. Ped Clin N Am 1983;30:397-404.
6. Dajani AS, Ferrieri P, Wannamaker LW. Natural history of impetigo II. Etiologic agents and bacterial interactions. J Clin Invest 1972;51:2863-2871.
7. Derrick CW, Dillon HC. Further studies on the treatment of streptococcal skin infection. J Pediatr 1970;77:696-700.
8. Barton LL, Friedman AD. Impetigo: a reassessment of etiology and therapy. Pediatr Dermatol 1987;4:185-188.
9. Barton LL, Friedman AD, Portilla MG. Impetigo contagiosa: a comparison of erythromycin and dicloxacillin therapy. Pediatr Dermatol 1988;5:88-91.
10. Barton LL, Friedman AD, Sharkey AM, et al. Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin. Pediatr Dermatol 1989;6:134-138.
11. Demidovich CW, Wittier RR, Ruff ME, et al. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child 1990;144:1313-1315.
12. Esterly NB, Nelson DB, Dunne WM. Impetigo. Am J Dis Child 1991;145:125-126.
13. Britton JW, Fajardo JE, Krafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr 1990;117:827-829.
14. Goldfarb J, Crenshaw D, O'Horo J, et al. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob Agents Chemother 1988;32:1780-1783.
15. Brook I, Frazier EH, Yeager JK. Microbiology of nonbullous impetigo. Pediatr Dermatol 1997;14: 192-195.
16. Coskey RJ, Coskey LA. Diagnosis and treatment of impetigo. J Am Acad Dermatol 1987;17:62-63.
17. Ferrieri P, Dajani AS, Wannamaker LW, Chapman SS. Natural history of impetigo I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci. J Clin Invest 1972;51:2851-2862.
18. Raviglione MC, Mariuz P, Pablos-Mendez A, et al. High Staphylococcus aureus nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex. Am J Infect Control 1990;18:64-69.
19. Barth JH. Nasal carriage of staphylococci and streptococci. Int J Dermatol 1987;26:24-26.
20. Noble WC, Williams REO, Jevons MP, Shooter RA. Some aspects of nasal carriage of Staphylococcus aureus. J Clin Pathol 1964;17:79-83.
21. Leyden JJ, Stewart R, Kligman AM. Experimental infections with Group A streptococci in humans. J Invest Dermatol 1980;75:196-201.
22. Dillon HC, Reeves MSA. Streptococcal immune responses in nephritis after skin infection. Am J Med 1974;56:333-346.
23. Weinstein L, Le Frock J. Does antimicrobial therapy of streptococcal pharyngitis or pyoderma alter the risk of glomemlonephritis? J Infect Dis 1971;124:229-231.
24. Melish ME. Staphylococci, streptococci and the skin. Review of impetigo and the staphylococcal scalded skin syndrome. Sem Dermatol 1982;1: 101-109.
25. Hirschmann JV. Topical antibiotics in dermatology. Arch Dermatol 1988;124:1691-1700.
26. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1992;36:287-290.
27. McLinn S. A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J Am Acad Dermatol 1990;22:883-885.
28. Mertz PM, Marshall DA, Eaglstein WH, et al. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol 1989;125:1069-1073.
29. McLinn S. Topical mupirocin vs. systemic erythromycin treatment for pyoderma. Pediatr Infect Dis J 1988;7:785-790.
30. Bass JW, Chan DS, Creamer KM, et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J 1997;16:708-710.
31. Booth JH, Benrimoj SI. Mupirocin in the treatment of impetigo. Int J Dermatol 1992;31:1-6.
32. Dagan R, Bar-David Y. Comparison of amoxicillin and clavulanic acid (Augmentin) for the treatment of nonbullous impetigo. Am J Dis Child 1989;143:916-918.
33. Maddox JS, Ware JC, Dillon HC. The natural history of streptococcal skin infection: prevention with topical antibiotics. J Am Acad Dermatol 1985;13:207-212.
34. Reagan DR, Doebbeling BN, Pfaller MA, et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991;114;101-106.
35. Doebbeling BN, Breneman DL, Neu HC, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis 1993;17:466-474.
36. Doebbeling BN, Reagan DR, Pfaller MA, et al. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994;154: 1505-1508.
37. Raz R, Miron D, Colodner R, et al. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996;156:1109-1112.
38. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med 1989;149:1258-1262.
39. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988;260:2682-2685.
40. Ladhani S, Joannou CL, Lochrie DP, et al. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded skin syndrome. Clin Microbiol Rev 1999;12:224-242.
41. Elias PM, Levy SW. Bullous impetigo. Occurrence of a localized scalded skin syndrome in an adult. Arch Dermatol 1976;112:856-858.
42. Helsing P, Gaustad P. Bullous impetigo caused by group A streptococci. A case report. Acta Derm Venereol 1992;72:50-51.
43. Hoeger PH, Lenz W, Boutonnier A, Foumier JM. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis 1992;165:1064-1068.
44. Aly R, Maibach HI, Shinefield HR. Microbial flora of atopic dermatitis. Arch Dermatol 1977; 113:780-782.
45. Masenga J, Garbe C, Wagner J, Orfanos CE. Staphylococcus aureus in atopic dermatitis and in nonatopic dermatitis. Int J Dermatol 1990;29:579-582.
46. Goodyear HM, Watson PJ, Egan SA, et al. Skin microflora of atopic eczema in first time hospital attenders. Clin Exper Dermatol 1993;18:300-304.
47. Hanifin JM, Rogge JL. Staphylococcal infections in patients with atopic dermatitis. Arch Dermatol 1977;113:1383-1386.
48. Leyden JJ, Marples RP, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974;90:525-530.
49. Nilsson DJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992;27: 29-34.
50. Stalder JF, Fleury M, Sourisse M, et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994;131:536-540.
51. Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976;95:323-328.
52. Davis CM, Fulghum DD, Taplin D. The value of neomycin in a neormycin-steroid cream. JAMA 1968;203:298-300.
53. Lloyd KM. The value of neomycin in topical corticosteroid preparations. South Med J 1969;62: 94-96.
54. Hjorth N, Schmidt J, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmathereutica 1985;4:126-131.
55. Leyden JJ, Kligman AM. The case for steroid-antibiotic combinations. Br J Dermatol 1977;96: 179-187.
56. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988;119:189-198.
57. Ewing CI, Ashcroft C, Gibbs ACC, et al. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol 1998;138:1022-1029.